Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature

Angela Burleigh; Nordau Kanigsberg; Joseph M Lam

doi:10.1111/pde.13596

Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature

Pediatr Dermatol. 2018 Sep;35(5):e286-e290. doi: 10.1111/pde.13596. Epub 2018 Jul 17.

Authors

Angela Burleigh¹, Nordau Kanigsberg², Joseph M Lam^{1

3}

Affiliations

¹ Department of Dermatology, University of British Columbia, Vancouver, BC, Canada.
² Division of Dermatology, University of Ottawa, Ottawa, ON, Canada.
³ Department of Paediatrics, University of British Columbia, Vancouver, BC, Canada.

PMID: 30015406
DOI: 10.1111/pde.13596

Abstract

The mTOR inhibitor rapamycin is used systemically for the treatment of vascular lesions. We report the first use of topical rapamycin for the successful treatment of two cases of tufted angioma. The evidence for the use of topical rapamycin in other dermatologic conditions is summarized to aid in clinical decision making on preparations and anticipated side effects.

Keywords: rapamycin; sirolimus; tufted angioma.

Publication types

Case Reports
Review

MeSH terms

Administration, Topical
Child
Female
Hemangioma / drug therapy*
Humans
Immunosuppressive Agents / administration & dosage*
Infant
Sirolimus / administration & dosage*
Skin Neoplasms / drug therapy*

Substances

Immunosuppressive Agents
Sirolimus

Supplementary concepts

Tufted angioma